The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Real-world, clinical practice data are lacking about sofosbuvir/ ribavirin (SOF/RBV) treatment of Korean patients with hepatitis C virus genotype 2 (HCV GT2) infection. This study investigated the efficacy and safety of SOF/RBV in Korean patients with HCV GT2 infection and clinical factors predicting sustained virological response 12 weeks (SVR12) after the end of SOF/RBV treatment. Methods: A total of 181 patients with HCV GT2 with/without cirrhosis were treated with SOF/RBV for 16/12 weeks. Rapid virological response (RVR) was defined as non-detectable HCV RNA at 4 weeks. Results: The RVR rate was 80.7% (146/181), the end of treatment response rate was 97.8% (177/181) and the SVR12 rate was 92.8% (168/181). Of eight patients with relapse, four did not achieve RVR. Three patients had a history of hepatocellular carcinoma (HCC). Multivariable analysis showed that RVR (p = 0.015) and no previous history of HCC (p = 0.007) were associated with SVR12. Factors significantly contributing to RVR included cirrhosis, creatinine concentration, and pre-treatment HCV RNA level. SVR12 rate was significantly higher in RVR (+) than RVR (–) patients (95.2% vs. 82.9%, p = 0.011) and also significantly higher in patients without than with a history of HCC (94.1% vs. 72.7%, p = 0.008). During treatment, 80/181 patients (44.2%) experienced mild to moderate adverse events, with 32 (17.7%) requiring RBV dose reductions due to anemia. Conclusions: SOF/RBV treatment was effective and tolerable in HCV GT2 patients. RVR and no previous history of HCC were positive predictors of SVR12.
Abstract
Background/Aims: Real-world, clinical practice data are lacking about sofosbuvir/ ribavirin (SOF/RBV) treatment of Korean patients with hepatitis C virus genotype 2 (HCV GT2) infection. This study investigated the efficacy and safety of SOF/RBV in Korean patients with HCV GT2 infection and clinical factors predicting sustained virological response 12 weeks (SVR12) after the end of SOF/RBV treatment. Methods: A total of 181 patients with HCV GT2 with/without cirrhosis were treated with SOF/RBV for 16/12 weeks. Rapid virological response (RVR) was defined as non-detectable HCV RNA at 4 weeks. Results: The RVR rate was 80.7% (146/181), the end of treatment response rate was 97.8% (177/181) and the SVR12 rate was 92.8% (168/181). Of eight patients with relapse, four did not achieve RVR. Three patients had a history of hepatocellular carcinoma (HCC). Multivariable analysis showed that RVR (p = 0.015) and no previous history of HCC (p = 0.007) were associated with SVR12. Factors significantly contributing to RVR included cirrhosis, creatinine concentration, and pre-treatment HCV RNA level. SVR12 rate was significantly higher in RVR (+) than RVR (–) patients (95.2% vs. 82.9%, p = 0.011) and also significantly higher in patients without than with a history of HCC (94.1% vs. 72.7%, p = 0.008). During treatment, 80/181 patients (44.2%) experienced mild to moderate adverse events, with 32 (17.7%) requiring RBV dose reductions due to anemia. Conclusions: SOF/RBV treatment was effective and tolerable in HCV GT2 patients. RVR and no previous history of HCC were positive predictors of SVR12.
참고문헌 (27)
- Gower E, "Global epidemiology and genotype distribution of the hepatitis C virus infection", J Hepatol, 61(1 Suppl), pp.S45~S57 (2014)
- Fattovich G, "Hepatocellular carcinoma in cirrhosis : incidence and risk factors", Gastroenterology, 127(5 Suppl 1), pp.S35~S50 (2004)
- Perz JF, "The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide", J Hepatol, 45, pp.529~538 (2006)
- Welzel TM, "Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection : results of the real-world, clinical practice HCV-TARGET study", Gut, 66, pp.1844~1852 (2017)
- Ju W, "Hepatitis C virus genotype and subtype distribution in Chinese chronic hepatitis C patients : nationwide spread of HCV genotypes 3 and 6", Virol J, 12, pp.109~ (2015)
- Toyoda H, "Changes in hepatitis C virus genotype distribution in Japan", Epidemiol Infect, 142, pp.2624~2648 (2014)
- Kim DY, "A nationwide seroepidemiology of hepatitis C virus infection in South Korea", Liver Int, 33, pp.586~594 (2013)
- Hae-Sook Shon, "Comparison and analysis of the prevalence of hepatitis C virus infection by region in the Republic of Korea during 2005–2012", Clinical and Molecular Hepatology, 21(3), pp.249~256 (2015), 대한간학회
- van der Meer AJ, "Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis", JAMA, 308, pp.2584~2593 (2012)
- Ioannou GN, "HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma", J Hepatol, 68, pp.25~32 (2018)
- AASLD, "IDSA HCV Guidance Panel", Hepatitis C guidance : AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus, 2015, pp.62, 932~954
- Lawitz E, "Sofosbuvir for previously untreated chronic hepatitis C infection", N Engl J Med, 368, pp.1878~1887 (2013)
- European Association for the Study of the Liver, "EASL recommendations on treatment of hepatitis C 2016", J Hepatol, 66, pp.153~194 (2017)
- Ahn SH, "A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus", J Viral Hepat, 23, pp.358~365 (2016)
- Omata M, "Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2HCV infection : an open-label, phase 3 trial", J Viral Hepat, 21, pp.762~768 (2014)
- Kao JH, "A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection", Liver Int, 36, pp.1101~1107 (2016)
- Mangia A, "Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis : a real life experience", J Hepatol, 66, pp.711~717 (2017)
- Wu CJ, "Real-world experience with sofosbuvir-based regimens for chronic hepatitis C, including patients with factors previously associated with inferior treatment response", Hawaii J Med Public Health, 74(9 Suppl 2), pp.3~7 (2015)
- Yu JW, "Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin", J Gastroenterol Hepatol, 22, pp.832~836 (2007)
- Sidharthan S, "Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy", Clin Infect Dis, 60, pp.1743~1751 (2015)
- Laperche S, "Interpretation of real-time PCR results for hepatitis C virus RNA when viral load is below quantification limits", J Clin Microbiol, 49, pp.1113~1115 (2011)
- Johnson K, "Implications of HCV RNA level at week 4 of direct antiviral treatments for hepatitis C", J Viral Hepat, 24, pp.966~975 (2017)
- Jacobson IM, "Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options", N Engl J Med, 368, pp.1867~1877 (2013)
- Kirby BJ, "Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir", Clin Pharmacokinet, 54, pp.677~690 (2015)
- Beste LA, "Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma", J Hepatol, 67, pp.32~39 (2017)
- Wirth TC, "The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma", Ann Oncol, 27, pp.1467~1474 (2016)
- Hengst J, "DAA-induced HCV clearance does not restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C", J Hepatol, 64(2 Suppl), pp.S417~S418 (2016)